Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06321523

A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Transthyretin Amyloid Cardiomyopathy Clinical Trial

Official title:
Clinical Benefit of Tafamidis 61mg for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Patients in Korean Population in the Real-world Setting, Multicenter, Non-interventional Study

Clinical Trial Summary

The purpose of this clinical trial is to learn about the effects of the study medicine (called Tafamidis 61milligrams (mg)) for the potential treatment of Transthyretin amyloid cardiomyopathy (ATTR-CM). This study is seeking participants who were prescribed Tafamidis 61mg after being diagnosed with ATTR-CM and have taken Tafamidis 61mg at least once. We will examine the experiences of people receiving the study medicine. This will help us determine if the study medicine is safe and effective.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06321523
Study type Observational
Source Pfizer
Contact
Status Active, not recruiting
Phase
Start date March 19, 2024
Completion date April 30, 2025
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Active, not recruiting NCT06257485 - Bronx Transthyretin Amyloid Cardiomyopathy Database
Recruiting NCT06086353 - A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in India
Completed NCT05233163 - SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy Phase 4
Not yet recruiting NCT06101108 - Early Diagnosis of Age-Linked CArdiac TransThyRetin Amyloidosis by Selective Screening in Spinal Stenosis Surgery
Completed NCT04814186 - A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Phase 4
Recruiting NCT04899180 - Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis Early Phase 1
Recruiting NCT05259072 - carDIo-ttranSSfOrm nucLEar Imaging Study Phase 3
Recruiting NCT06183931 - Study of ALXN2220 Versus Placebo in Adults With ATTR-CM Phase 3
Recruiting NCT06328075 - Artificial Intelligence to Assist the Echocardiographic Identification of Transthyretin Cardiac Amyloidosis
Recruiting NCT06291805 - Phenotyping and Characterization of wtATTR-CM (TRACE 1)
Terminated NCT04424914 - Global Prevalence of ATTR-CM in Participants With HFpEF N/A
Recruiting NCT06194825 - EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy Phase 3
Recruiting NCT06372301 - Dobutamine Stress Echocardiography in LF/LG Aortic Stenosis and Wild-type Transthyretin Amyloid Cardiomyopathy N/A